Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, Chen Y, Narayaraswamy R, Tong S, Wang F, Zhou D, Cui D, Cai Z, Luo Z, Fang C, Tang H, Lv X, Nagaraja R, Yang H, Su SM, Sui Z, Dang L, Yen K, Popovici-Muller J, Codega P, Campos C, Mellinghoff IK, Biller SA. Konteatis Z, et al. Among authors: mellinghoff ik. ACS Med Chem Lett. 2020 Jan 22;11(2):101-107. doi: 10.1021/acsmedchemlett.9b00509. eCollection 2020 Feb 13. ACS Med Chem Lett. 2020. PMID: 32071674 Free PMC article.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA. Turcan S, et al. Among authors: mellinghoff ik. Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866. Nature. 2012. PMID: 22343889 Free PMC article.
Imaging tumor burden in the brain with 89Zr-transferrin.
Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Evans MJ, et al. Among authors: mellinghoff ik. J Nucl Med. 2013 Jan;54(1):90-5. doi: 10.2967/jnumed.112.109777. Epub 2012 Dec 12. J Nucl Med. 2013. PMID: 23236019 Free PMC article.
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. Rohle D, et al. Among authors: mellinghoff ik. Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4. Science. 2013. PMID: 23558169 Free PMC article.
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. de la Fuente MI, et al. Among authors: mellinghoff ik. Neuro Oncol. 2016 Feb;18(2):283-90. doi: 10.1093/neuonc/nov307. Epub 2015 Dec 20. Neuro Oncol. 2016. PMID: 26691210 Free PMC article.
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O, Yen K, Mellinghoff IK. Clark O, et al. Among authors: mellinghoff ik. Clin Cancer Res. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27. Clin Cancer Res. 2016. PMID: 26819452 Free PMC article. Review.
Dissecting Glioma Invasiveness in a 3D-Organotypic Model.
Codega P, Mellinghoff IK. Codega P, et al. Among authors: mellinghoff ik. Trends Mol Med. 2017 Sep;23(9):776-777. doi: 10.1016/j.molmed.2017.07.009. Epub 2017 Aug 3. Trends Mol Med. 2017. PMID: 28781061 Free PMC article.
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Among authors: mellinghoff ik. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19. Blood. 2019. PMID: 30567753 Free PMC article. Clinical Trial.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD, Pandya SS, Manyak E, Jiang L, Liu G, Nimkar T, Gliser C, Prahl Judge M, Agresta S, Yang H, Dai D. Fan B, et al. Among authors: mellinghoff ik. Invest New Drugs. 2020 Apr;38(2):433-444. doi: 10.1007/s10637-019-00771-x. Epub 2019 Apr 26. Invest New Drugs. 2020. PMID: 31028664 Free PMC article. Clinical Trial.
148 results